Reporter brief
Senolytic fisetin tested in RCT to reduce organ failure in sepsis patients
What happened
This is a phase II, multicenter randomized trial testing different doses of the senolytic drug fisetin in older patients with sepsis. The primary outcome is a composite score of cardiovascular, respiratory, and renal organ failure at 1 week. No results are reported in this abstract—only the study design, hypothesis, and intended outcomes are described.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Older patients with sepsis
- Design
- Rct
- Sample
- —
- Journal
- University of Minnesota
- Published
- Sep 1, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.